The Impact of Anvisa Regulations on Medicines, Medical Devices, Cosmetics, and Supplements
This blog post discusses recent ANVISA regulatory changes that directly impact the industries of medicines, medical devices, cosmetics, and sanitizing products, as well as dietary supplements. The goal is to provide a practical guide for regulatory affairs companies, such as GRP Brazil, to anticipate and adjust their processes, ensuring compliance and operational efficiency.
China’s NMPA announces that it will expedite review applications for the marketing of Novel Drugs.
China’s CDE has released “Working Procedure for Accelerating the Review of Marketing Application of Innovative Drugs (Trial Implementation)”(hereinafter referred to as “Working Procedure”) for industry comments due March 4th, 2022.